Clinical Trials Logo

Clinical Trial Summary

Electrical stimulation of the foot can increase blood flow out of the leg. This increased blood flow can prevent blood clots from forming in the leg veins.

Blood clots in the leg veins can break off and form life-threatening blood clots in the lungs.

Intermittent external pneumatic (air) compression of the foot is already used to increase blood flow in at risk patients.

Hypothesis: Electrical stimulation of the foot increases blood flow out of the legs to the same degree as intermittent external pneumatic (air) compression of the foot.


Clinical Trial Description

ABSTRACT Background: Venous stasis caused by immobility is an important risk factor for venous thromboembolic disease. This is especially true for orthopedic patients with multiple trauma and those undergoing other orthopedic procedures. A safe and convenient method for reducing venous stasis would be useful for preventing venous thrombosis in patients while in hospital and particularly after discharge during rehabilitation. In a prior study, we demonstrated that electrical stimulation of the foot was a safe and convenient method for counteracting venous stasis. In this study, we compare the effects on venous blood flow of intermittent pneumatic compression, an established method, to electrical stimulation of the foot.

Methods: 40 healthy volunteers aged 50 - 80 were seated for 4 hours during which they received mild electrical stimulation of the sole of the foot (plantar plexus of muscles) or intermittent pneumatic compression. Popliteal and femoral venous blood flow velocities were measured via Doppler ultrasound. Blood flow in the non-stimulated or non-compressed lower extremity served as a simultaneous control. Subjects completed a questionnaire regarding their acceptance and tolerance of both treatments.

INTRODUCTION Venous thrombosis and pulmonary embolism or venous thromboembolism (VTE) are important complications of medical and surgical conditions that are associated with prolonged immobilization. This is especially true for orthopedic patients with multiple trauma and those undergoing other orthopedic procedures. Immobilization is also a major contributor to the increased risk of VTE associated with prolonged air travel.

Despite good evidence that prophylaxis is effective, there is widespread under utilization of prophylaxis for VTE following major surgical procedures as well as medical conditions that produce weakness or prolonged bed rest. There is also good evidence that the risk of VTE continues for weeks after major orthopedic as well as other types of surgery. It is now recognized that VTE occurring in the hospital and outside the hospital setting is a single entity and that extended prophylaxis with anticoagulants reduces the risk.

Anticoagulant prophylaxis after hospital discharge although indicated in certain high risk groups is inconvenient since the recommended methods, LMWH and fondaparinux must be administered by subcutaneous injection and warfarin requires laboratory monitoring.

Physical methods that increase blood flow in the leg veins are effective for reducing venous thrombosis in high-risk hospitalized medical and surgical patients. These methods include: high intensity electrical calf stimulation during surgery, graduated compression stockings and intermittent pneumatic compression of the leg or foot. Of these, only graduated compression stockings, which are not very effective, can be used after hospital discharge. Graduated compression stockings, however, cannot be adapted to fit all leg shapes, may be improperly applied, have a tendency to slip down the leg and are found to be uncomfortable by many patients. High intensity electrical calf muscle stimulation is painful and can only be used during general anesthesia. AC powered external pneumatic compression can only be used while the patient is fully immobilized. Thus, alternative convenient methods are needed which can be used both in the immobilized and partly mobile patient, particularly after hospital discharge.

We have attempted to overcome the limitations of currently available physical devices by using mild electrical stimulation of the plantar muscles of the feet. Each electrical discharge elicits a foot twitch that causes the intrinsic foot muscles to contract. This contraction compresses the plantar plexus of veins, thereby increasing venous velocity in the popliteal and femoral veins that is transmitted proximally up the leg veins.

Our plantar foot stimulation device is powered by a 9-volt battery and small enough to be inserted into a sock. It has the potential to be worn while a patient is immobile, standing or walking, and therefore is suitable for use both during the initial period of immobilization and throughout convalescence.

In an earlier study we reported that mild electrical stimulation of the plantar foot muscles caused an increase in blood flow comparable to that produced by direct calf stimulation.

The aim of this new study is to determine if, over a 4 hour period, mild electrical stimulation of the plantar foot muscles increases venous blood flow velocity to the same degree as intermittent pneumatic compression (IPC) of the leg in both obese and non-obese subjects.

MATERIALS AND METHODS IRB approval and informed consent was obtained from all subjects. Forty healthy subjects (N = 40) between the ages of 50 to 80 participated in the study. Half of the subjects (N = 20) were non-obese with a Body Mass Index (BMI) < 30. The other half of the subjects (N = 20) were obese with a BMI > 30. Exclusion criterion included a prior history of deep vein thrombosis or pulmonary embolism, or any trauma or surgery involving any part of the lower extremities.

Subjects were studied over 2 sessions. At each session, subjects received either electrical foot stimulation or intermittent pneumatic compression of one foot. The other lower extremity served as a control. Subjects received either therapy at one session and the other therapy at a second session at least 48 hours later. The right or left leg of each subject was randomly assigned as the same control leg for both studies. The type of therapy given at the first session was also randomly assigned.

The study otherwise followed the protocol used in our initial study of electrical foot stimulation. Subjects were seated for 4 hours in chairs placed at a fixed distance apart. They were constantly monitored throughout the study to ensure that they remained seated. Subjects were allowed to use a bathroom located several feet away only twice during the 4 hour period. During the 4 hour study period subjects were offered a maximum of 16 ounces of fluid and a normal lunch.

Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by the Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds "on" and 48 seconds "off" per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.

Intermittent pneumatic compression of the leg consisted of external intermittent pneumatic compression with a knee high device. A Tyco Healthcare Kendall Novamedix A-V impulse system® Model 6060 (Mansfield, MA 02048) was used. Operating parameters were: 130mmHg impulse pressure with a 3 second impulse duration; "Program Preset 1" for deep vein thrombosis prophylaxis. The compression followed the approved standard patient protocol used at our institution detailed in "Utilization of Intermittent Pneumatic Compression (IPC) Stockings for DVT Prophylaxis".

Popliteal and femoral venous peak blood flow velocities were measured bilaterally using a Doppler ultrasound device at 0, 15, 120, and 240 minutes. The same ultrasound technician obtained all Doppler studies on all subjects throughout the study. All Doppler tracings were be read by the same independent reader in a blinded fashion. Immediately following completion of each 4 hour session of electrical foot stimulation or intermittent pneumatic compression, subjects were asked to complete a brief questionnaire regarding their acceptance and tolerance of electrical stimulation or intermittent pneumatic compression.

STATISTICAL METHODS This study utilized a repeated measures design with two within group factors: time to measurement, and stimulation (stimulation, control). Stimulation groups [electrical foot stimulation and intermittent pneumatic compression (IPC)] were not independent. Blood flow measurements (at time = 120, 240) were analyzed with t tests and a mixed model. Within the mixed model, the group effect is a fixed effect, and the subject parameter is a random effect. The primary research question was the non-inferiority of the experimental treatment (electrical foot stimulation) relative to standard treatment (intermittent pneumatic compression). The non-inferiority index was 5.0 cm/sec; this index was formulated prior to analysis. The questionnaire results were analyzed using Fisher's Exact test. P-values that were less than 0.05 were considered to be statistically significant. All analyses were done with SAS 9.1, Cary, NC. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00114608
Study type Interventional
Source University at Buffalo
Contact
Status Completed
Phase Phase 1
Start date June 2005
Completion date July 2007

See also
  Status Clinical Trial Phase
Recruiting NCT05050617 - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Terminated NCT03002467 - Impact Analysis of Prognostic Stratification for Pulmonary Embolism N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2